Products

2,2,4,6,7-Pentamethyldihydrobenzofuran Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable

    • Product Name: 2,2,4,6,7-Pentamethyldihydrobenzofuran Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable
    • Factroy Site: Yudu County, Ganzhou, Jiangxi, China
    • Price Inquiry: admin@ascent-chem.com
    • Manufacturer: Ascent Petrochem Holdings Co., Limited
    • CONTACT NOW
    Specifications
    HS Code 150656
    Product Name 2,2,4,6,7-Pentamethyldihydrobenzofuran Pharma Grade API
    Chemical Name 2,2,4,6,7-Pentamethyl-2,3-dihydro-1-benzofuran
    Cas Number 20571-42-1
    Molecular Formula C13H18O
    Molecular Weight 190.28 g/mol
    Synonyms 2,2,4,6,7-Pentamethyl-2,3-dihydrobenzofuran; Pentamethyldihydrobenzofuran; PMDB
    Appearance Clear colorless to light yellow liquid
    Purity >=99.0% assay (HPLC)
    Solubility Freely soluble in ethanol, methanol, DMSO, chloroform and ethyl acetate; practically insoluble in water
    Density Approximately 0.96 g/cm3 at 20°C
    Boiling Point Approximately 240°C at 760 mmHg
    Storage Conditions Store in a cool, dry, well-ventilated area; protect from light; keep container tightly closed
    Grade Pharma Grade
    Suitable Dosage Forms Tablet, capsule, granule, and injection; oral and injectable routes
    Product Name 2,2,4,6,7-Pentamethyldihydrobenzofuran Pharma Grade API
    Chemical Identity 2,2,4,6,7-Pentamethyl-2,3-dihydrobenzofuran
    Chemical Class Dihydrobenzofuran derivative
    Molecular Formula C13H18O
    Molecular Weight 190.28 g/mol
    Physical Appearance Clear, colorless to pale yellow liquid
    Density Approximately 0.94 g/cm3 at 20°C
    Boiling Point Approximately 250°C
    Solubility Soluble in ethanol, DMSO, and acetone; practically insoluble in water
    Purity Minimum 99.0% by HPLC
    Residual Solvents Complies with ICH Q3C limits
    Storage Conditions Store in a tightly closed container in a cool, dry place; protect from light
    Shelf Life 24 months under recommended storage conditions
    Dosage Form Compatibility Suitable for tablet, capsule, granule, and injection formulations
    Route Of Administration Oral and injectable

    As an accredited 2,2,4,6,7-Pentamethyldihydrobenzofuran Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Pharma Grade API supplied as 25 kg sealed polyethylene-lined drums, protected from moisture, for oral and injectable dosage manufacturing.
    Container Loading (20′ FCL) 20′ FCL container loading of pharma-grade 2,2,4,6,7-Pentamethyldihydrobenzofuran API for tablet, capsule, granule, and injectable formulations.
    Shipping Ship as temperature-controlled, moisture-proof, light-protected cargo. Pack in sealed, food-grade polyethylene-lined fiber drums or sterile double-bag containers. Avoid contact with metals and strong oxidizers. Label per IATA/IMDG and local dangerous goods regulations. Include certificate of analysis, batch number, and handling documentation. Maintain segregation from food and direct heat to preserve purity.
    Storage Store the 2,2,4,6,7-Pentamethyldihydrobenzofuran Pharma Grade API in a tightly closed, original or validated container in a cool, dry, well-ventilated area at controlled room temperature (15–25°C). Protect from light, moisture, and excessive humidity. Keep away from oxidizing agents and incompatible materials. Do not freeze. Follow label instructions and use within expiry. For injectable use, maintain aseptic handling after opening.
    Shelf Life Store in a cool, dry place. Shelf life is 24 months from manufacture when stored properly in original container.
    Application of 2,2,4,6,7-Pentamethyldihydrobenzofuran Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable
    Before direct compression is selected for 2,2,4,6,7-Pentamethyldihydrobenzofuran pharma-grade active ingredient, particle-size distribution and flow must pass USP 1174 criteria. A representative tablet core is 200 mg with a 20 mg active dose; the arithmetic active fraction is 10% w/w. Direct-compression blends are prepared with 45–75% w/w microcrystalline cellulose, 2–4% w/w crospovidone, and 0.5–1.5% w/w magnesium stearate. The active ingredient is screened through a 0.5 mm mesh before blending to break agglomerates. Blending is performed in a bin blender at 20–25 rpm for 10–15 minutes; magnesium stearate is added during the final 3–5 minutes because over-lubrication reduces tablet hardness and slows dissolution. Compaction runs on a rotary tablet press at 10–30 kN compression force with a target tablet hardness of 60–120 N. Weight variation and content uniformity are tested under USP 905. Dissolution is performed with USP Apparatus II at 50 rpm in 900 mL of pH 6.8 phosphate buffer; media selection is confirmed by the pH-solubility profile. If published data for this specific configuration are limited, solubility screening in pH 1.2, 4.5, and 6.8 buffers must be completed before dissolution method finalization. Elemental impurities are controlled under ICH Q3D; for an oral daily dose below 10 g, the permitted daily exposures are 5 µg lead, 2 µg cadmium, 15 µg arsenic, and 3 µg mercury. The finished immediate-release tablet is film-coated at 2–4% weight gain in a perforated pan coater with inlet air at 40–55°C. The coating system is aqueous; no organic coating solvent is used. If ambient relative humidity exceeds 60%, pre-conditioning of the blend and extended drying of the coated tablets are required to prevent picking and moisture-induced dissolution shift.

    What Changes When the Active Ingredient Is Filled into Hard Gelatin Capsules?

    Capsule filling shifts blend flow requirements from tablet compression to plug formation and powder bed uniformity. A size 3 hard shell filled with 150 mg of blend containing 15 mg active ingredient yields 10% w/w active fraction. Capsule-specific flow is characterized by USP 1174 using bulk density, tapped density, and angle of repose; poor flow is more severe in dosator machines than in tamping-pin machines. Tamping-pin encapsulation equipment must hold plug height reproducibility within ±3% relative standard deviation across 100 filling cycles. HPMC capsule shells require equilibrium moisture control; if shell moisture exceeds 8–10% w/w, brittle fracture or sticking on the capsule bushing occurs. Disintegration is tested by USP 701; the target disintegration time is ≤15 minutes in water at 37±2°C. Content uniformity is tested by USP 905. Dissolution is performed by USP 711 with USP Apparatus II at 50 rpm; capsules are weighed down with a wire sinker to prevent floating. Gelatin cross-linking is monitored if the fill contains reactive aldehydes; formaldehyde contamination above 10 ppm in excipients can produce pellicle formation and dissolution failure. The finished article is a hard-shell capsule, either gelatin or HPMC, with colorant loading of 0.1–0.5% w/w in the shell mass. If the active ingredient is moisture-sensitive, the capsule fill may include a desiccant canister and a moisture-permeable HDPE closure.

    Wet Granulation Parameters and Binder Addition Thresholds

    When poor flow or low bulk density limits direct compression, wet granulation is selected for 2,2,4,6,7-Pentamethyldihydrobenzofuran oral solid forms. The dry blend is formulated with 10–20% w/w active ingredient, 55–75% w/w lactose monohydrate or microcrystalline cellulose, 3–6% w/w povidone K30, and 0.5–2% w/w crospovidone. Purified water or aqueous binder solution is added at 20–35% w/w of dry mass. The granulation endpoint is determined by impeller torque or power draw on a high-shear mixer; main impeller speed is 200–400 rpm and chopper speed is 1000–2500 rpm. Wet massing time is limited to 2–5 minutes because over-granulation creates dense granules that resist disintegration. Drying in a fluid-bed dryer is run at inlet air temperature 50–70°C until loss on drying by USP 731 reaches 1.0–2.5% w/w. Milling through 0.8–1.2 mm screen controls oversized material; particles above 850 µm and fines below 75 µm are limited because they change die fill and weight variation. Particle size distribution is measured by sieve analysis under USP 786. Residual water is a critical process parameter; final granule LOD is specified at ≤2.0% w/w for moisture-sensitive active ingredients. The granules are compressed into tablets or filled into capsules. During compression, a precompression force of 2–5 kN followed by main compression of 10–25 kN reduces capping. The finished dose form is tested for dissolution by USP 711 and uniformity by USP 905. If the active ingredient is moisture-sensitive, mannitol is preferred over lactose to avoid reducing sugar interactions.Dry granulation by roller compaction is run when the compound is moisture-sensitive or when wet granulation creates stability risks. The pre-blend contains 10–30% w/w active ingredient, 55–80% w/w microcrystalline cellulose, 2–5% w/w crospovidone, and 0.5–1.0% w/w magnesium stearate. Roller pressure is set at 4–8 kN/cm on a pharmaceutical roller compactor with a roll gap of 2–4 mm and roll diameter of 100–200 mm. Ribbon density is monitored at 1.1–1.4 g/cm³; lower ribbon density produces too many fines, while higher ribbon density reduces granule porosity and slows dissolution. Ribbons are milled through 0.8–1.5 mm screens. Fines below 75 µm are limited to 20–40% w/w of the granule mass; if fines exceed 40%, the roller pressure is reduced or the fines are recompacted. Bulk density, tapped density, and compressibility index are measured under USP 1174. The dry granulation route avoids aqueous binder exposure and therefore simplifies residual solvent compliance; ICH Q3C Class 1 solvents benzene and carbon tetrachloride must remain below 2 ppm and 4 ppm, respectively. The granules are compressed into tablets or filled into capsules. Dissolution is tested by USP 711 because roller compaction can reduce effective surface area compared with direct compression. Uniformity is tested by USP 905. The finished article is a tablet or capsule produced without an aqueous drying step.
    RouteAPI fraction (% w/w)Key process variableCritical test
    Direct compression5–40%10–30 kN compression forceUSP 905, USP 711
    Hard capsule filling5–25%Plug height RSD ±3%USP 905, USP 701
    Wet granulation10–20%LOD 1.0–2.5% w/wUSP 731, USP 786
    Roller compaction10–30%Roller pressure 4–8 kN/cmUSP 1174, USP 711

    When the API Must Pass Sterility Assurance for Small-Volume Parenterals

    For injectable solution development, the first constraint is aqueous solubility. The compound has a molecular weight of 190.29 g/mol; the dihydrobenzofuran ring lacks a phenolic hydrogen, so pH-dependent ionization is likely absent. Solubility must be confirmed by the shake-flask method under USP 1236 in water, pH 4.5 acetate buffer, and pH 7.4 phosphate buffer. If an aqueous solution cannot reach the target label concentration, a co-solvent system of propylene glycol, polyethylene glycol 300, or ethanol is selected. Ethanol is limited by ICH Q3C as a Class 3 solvent with a permitted daily exposure of 5000 ppm or 50 mg/day; for a 10 mL injection volume, the ethanol content must not exceed 50 mg per unit. Tonicity is adjusted with sodium chloride or mannitol to 270–330 mOsmol/kg by USP 785. pH is adjusted to 5.0–7.0 with dilute hydrochloric acid or sodium hydroxide to reduce glass delamination in USP Type I borosilicate vials. The bulk solution is filtered through a 0.22 µm sterilizing-grade membrane. Terminal moist-heat sterilization at 121°C for 15 minutes is validated to ISO 17665; if thermal stability of the active ingredient is not demonstrated, aseptic filtration and filling are used instead. Aseptic filling is performed in an ISO 14644-1 Class 5 environment. Sterility is tested by USP 71. Bacterial endotoxin limits are calculated from the dose: for intravenous administration at 1 mg/kg, the limit is 5 EU/mg. Particulate matter is tested by USP 788; the small-volume parenteral must contain no more than 6000 particles ≥10 µm and 600 particles ≥25 µm per container. Fill volume and container closure integrity are controlled under 21 CFR 211.94. The finished product is a clear solution in a 10 mL USP Type I glass vial sealed with a chlorobutyl rubber stopper and aluminum crimp seal.Lyophilized injectable formulations shift stability burden from solution to the dried matrix and allow the active ingredient to be stored below its degradation threshold. Pre-formulation studies determine the collapse temperature by freeze-dry microscopy and the glass transition temperature by differential scanning calorimetry. A typical pre-lyophilization solution contains the active ingredient at 1–10 mg/mL, mannitol as bulking agent at 2–5% w/v, and trehalose as lyoprotectant at 2–5% w/v. A 5 mL fill of a 2 mg/mL solution yields 10 mg per vial. The solution is filtered through a 0.22 µm membrane and filled into 10 mL vials. Freezing is performed at shelf temperature -40°C to -50°C; primary drying is run below the collapse temperature with chamber pressure of 0.1–0.2 mbar. Secondary drying is performed at 25–40°C shelf temperature until residual moisture reaches ≤1.0% w/w by USP 921. The lyophilized cake is inspected for collapse, meltback, and shrinkage. Reconstitution with water for injection should produce a clear solution in ≤2 minutes; the reconstituted solution is tested for particulate matter under USP 788. Sterility is tested by USP 71. Endotoxin is tested by USP 85; for a 10 mg vial dosed at 1 mg/kg, the endotoxin limit is 5 EU/mg. Extractables and leachables from the elastomeric stopper are assessed under USP 1663 and USP 1664. The finished product is a lyophilized cake for reconstitution before intravenous or intramuscular administration.
    Quality attributeTest methodAcceptance limit or target
    SterilityUSP 71No growth after 14 days
    Bacterial endotoxinsUSP 85≤ 5 EU/mg at 1 mg/kg IV dose
    Particulate matterUSP 788≤ 6000 particles ≥10 µm, ≤ 600 particles ≥25 µm per container
    OsmolalityUSP 785270–330 mOsmol/kg
    Residual moisture, lyophilizedUSP 921≤ 1.0% w/w
    Extractables/leachablesUSP 1663, USP 1664Reported and toxicologically assessed per USP 1664

    Oral Granules in Unit-Dose Sachets and Reconstitution Powders

    In unit-dose sachet manufacturing, the finished dose must be suspended or dissolved before oral administration; therefore the active ingredient is granulated onto a carrier such as mannitol, sorbitol, or lactose monohydrate. A 20 mg dose filled to 500 mg total granule mass gives 4% w/w active fraction. Fluid-bed top-spray granulation is performed with povidone K30 as binder at 2–5% w/w sprayed at 10–20 g/min per kg substrate. Inlet air temperature is 50–65°C, product temperature is 30–40°C, and drying continues to a loss on drying of ≤2.0% w/w by USP 731. Particle size is controlled by laser diffraction under USP 429; the target D50 is 150–300 µm and D90 is ≤850 µm to ensure complete dispersion. The granules are filled into low-moisture-permeation sachet film; fill weight variation is controlled to ±5% of target. Dispersion is checked by adding one sachet to 100 mL water at 20–25°C; the suspension should disperse in ≤3 minutes with gentle swirling. Dissolution testing, if required, uses USP 711 Apparatus II at 50 rpm. Residual solvents are controlled under ICH Q3C; methanol must remain below 3000 ppm and ethanol below 5000 ppm. The finished product is a single-dose sachet that is opened and mixed with water immediately before oral administration.
    Free Quote

    Competitive 2,2,4,6,7-Pentamethyldihydrobenzofuran Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615365186327

    Email: admin@ascent-chem.com

    Inquiry

    Get Free Quote of Ascent Petrochem Holdings Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Get A Free Quote Now
    Certification & Compliance
    More Introduction

    2,2,4,6,7-Pentamethyldihydrobenzofuran Pharma Grade API is supplied under model designation PMDBF-PH/API-07 for GMP-controlled use in tablet, capsule, granule, oral, and injectable process trains. The IUPAC name is 2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran; the molecular formula is C13H18O and the molar mass is 190.28 g/mol. The material is a small-molecule active pharmaceutical ingredient released under ICH Q7 expectations, with batch-specific certificates of analysis, change control, stability commitments, and qualified analytical methods. No public pharmacopeial monograph for this exact molecule currently exists in USP, Ph. Eur., or JP; therefore, the specification is supplier-qualified and aligned with ICH Q3A, Q3C, Q3D, USP <61>/<62>, and USP <85> for injectable applications. The pharma grade product differs from technical or reagent grade by controlled particle size, residual solvents, elemental impurities, microbiological quality, and endotoxin testing. Published formulation, pharmacokinetic, and stability data for this specific configuration are limited; process qualification should therefore be generated for each dosage form before commercial use.

    The model designation is referenced in specification document QA-SPEC-API-028. The certificate of analysis reports appearance, identification, assay, related substances, residual solvents, loss on drying, residue on ignition, elemental impurities, particle size distribution, microbial enumeration, and bacterial endotoxins. Injectable-destined lots are segregated from oral-destined lots at the warehouse level, and both are stored in tightly closed, light-resistant containers at 20–25°C.

    What analytical release criteria separate this pharma grade from technical-grade material?

    The release profile uses identity, assay, impurity, and microbiological controls that are absent or less stringent in non-GMP material. Identification by mid-infrared absorption spectrophotometry is performed against a qualified reference standard. The HPLC assay uses a reversed-phase C18 column of 150 mm × 4.6 mm, 5 μm particle size, with an acetonitrile–aqueous mobile phase containing 0.1% formic acid or phosphoric acid. The flow rate is 1.0 mL/min, the column temperature is 30°C, and UV detection is selected after scanning; the acceptance interval is 98.0% to 102.0% on the anhydrous and solvent-free basis. Impurity controls follow ICH Q3A thresholds for a maximum daily dose of 2 g/day or less, yielding an unspecified individual impurity limit of ≤0.10% and a total impurity limit of ≤0.5%.

    Residual solvents are measured by headspace gas chromatography on a DB-624 30 m × 0.32 mm × 1.8 μm column with flame ionization detection. Class 3 solvents are controlled at ≤0.5% each under ICH Q3C. Any Class 2 solvent used in the final synthetic step is controlled according to ICH Q3C Option 2; if dichloromethane or pyridine is present, the concentration is typically limited to ≤0.2% combined. Loss on drying is ≤0.5% by USP <731>; residue on ignition is ≤0.1% by USP <281>. Elemental impurities are assessed under ICH Q3D Option 1 for parenteral administration; arsenic, lead, cadmium, mercury, cobalt, vanadium, and nickel are controlled to the applicable permitted daily exposure limits.

    ParameterMethod / StandardRelease Limit
    AppearanceVisual inspectionWhite to off-white crystalline powder
    IdentificationIR, Ph. Eur. 2.2.24 / USP <197>Matches reference spectrum
    AssayHPLC, ICH Q2(R1)98.0%–102.0% on anhydrous basis
    Total impuritiesHPLC≤0.5%
    Unspecified individual impurityHPLC≤0.10%
    Loss on dryingUSP <731>≤0.5%
    Residue on ignitionUSP <281>≤0.1%
    Elemental impuritiesUSP <232>/<233> / ICH Q3DParenteral PDE values as per ICH Q3D Option 1
    Microbial enumerationUSP <61>/<62>TAMC ≤1000 CFU/g oral; ≤100 CFU/g injectable; TYMC ≤100 CFU/g; Escherichia coli absent
    Bacterial endotoxinsUSP <85>≤0.25 EU/mg for injectable-destined material
    Particle sizeLaser diffraction, ISO 13320D90 ≤250 μm oral; D90 ≤50 μm injectable

    Microbial method suitability is performed per USP <61>/<62> or Ph. Eur. 2.6.12/2.6.13 for each new supplier batch because the API itself may inhibit recovery in tryptic soy agar if it is poorly water-wettable. For injectable-destined API, bacterial endotoxin testing by kinetic chromogenic limulus amebocyte lysate is performed after appropriate sample dilution; endotoxin release is ≤0.25 EU/mg. The default limit is intended to allow final drug-product endotoxin limits to be calculated from the K/M method in USP <85>; it is not a guarantee of safety without the final dose calculation.

    Particle engineering and powder rheology for tablet, capsule, and granule platforms

    For oral solid dose processing, the API is supplied as a milled or micronized powder. The oral-destined grade has D90 ≤250 μm, while direct compression at low dose strengths may require tighter control such as D90 ≤100 μm. Blend uniformity is evaluated by USP <905> stratified sampling with acceptance of relative standard deviation ≤5.0% for a 10 mg dose. Because published powder shear data for this specific compound are limited, a ring shear tester or a Hosokawa powder tester is used to determine flow function coefficient; if flow function coefficient is below 4.0, colloidal silicon dioxide at 0.5–1.0% is added before tableting or capsule filling.

    Wet granulation uses a high-shear mixer or fluid-bed granulator. Hydroxypropyl cellulose at 2% w/w in purified water is added by peristaltic pump; endpoint is controlled by impeller torque or power consumption at 80% of the predetermined target. The granulation is dried at inlet air temperature 50–60°C until loss on drying is ≤2.0%. If the API shows oxidative sensitivity in forced degradation, nitrogen blanketing of the drying inlet air is used. No public autooxidation data for this compound are available.

    Roller compaction is preferred for a moisture-sensitive API. A Gerteis Mini-Pactor or equivalent is operated at roll pressure 30–70 bar and roll gap 2 mm; the ribbons are milled through a 0.8–1.25 mm screen. Tablet compression on a rotary press uses 10–25 kN compression force and 5–20 rpm; tablet hardness is maintained at 60–100 N. Capsule filling uses a dosator or tamping-pin machine; dissolution is tested by USP <711> Apparatus II at 75 rpm in 900 mL of pH 6.8 phosphate buffer. Because the compound is lipophilic, dissolution in aqueous media may be solubility-limited; the formulation may require surfactant or co-milling with mannitol or crospovidone to achieve acceptable release.

    When the API is specified for injectable presentations, the injectable grade carries microbial and endotoxin controls that are not needed for oral-destined material. The powder is not supplied as sterile; it is sterilized or aseptically processed during drug product manufacturing. The injectable grade has D90 ≤50 μm and bioburden ≤100 CFU/g. The bacterial endotoxin release limit of ≤0.25 EU/mg is a conservative default; the final drug-product endotoxin limit is determined by the dose and patient mass using USP <85> K/M, with K = 5 EU/kg for intravenous administration and K = 0.2 EU/kg for intrathecal administration. Published pharmacokinetic data for this molecule are limited, so maximum parenteral dose cannot be assumed from chemical similarity.

    Injectable vehicle design must address the low aqueous solubility expected from the lipophilic methylated dihydrobenzofuran scaffold. Co-solvent screening includes PEG 300 or propylene glycol at 10–40% and polysorbate 80 at 0.1–0.5%. If a clear solution is not achieved, sulfobutylether-β-cyclodextrin may be evaluated, but no inclusion-complex stability data for this specific compound are available in public references. Terminal steam sterilization at 121°C for 15 min is suitable only after forced degradation studies per ICH Q1A demonstrate assay loss <10% and no unidentified degradation product exceeding ICH identification thresholds. Aseptic filtration through a 0.22 μm sterilizing-grade polyethersulfone or polyvinylidene fluoride membrane is the conventional alternative when thermal stability is not established.

    The terminal sterilizing autoclave is qualified with Geobacillus stearothermophilus biological indicators targeting an F0 of ≥15 min when overkill sterilization is selected. Container-closure integrity is tested by dye ingress or vacuum decay according to USP <1207>. Subvisible particulate control follows USP <787> for small-volume injectables or USP <788> for large-volume injectables; light obscuration is performed with a HIAC AccuSizer or equivalent. Because the API is hydrophobic, particles may form upon dilution with saline; the formulation is screened by dynamic light scattering or light obscuration after 24 h storage at 2–8°C and at 20–25°C.

    If lyophilization is needed, a conservative freeze-drying cycle uses primary drying at shelf temperature -30°C to -20°C and chamber pressure 80–120 mTorr, followed by secondary drying at 25–40°C for 4–8 h. Collapse temperature is determined by freeze-drying microscopy; published collapse data for this exact material are limited. If gamma irradiation of the dried API is considered, no published radiation degradation data for this molecule were identified; radiolytic degradant profiling and physical comparison to unirradiated control are required before use.

    When the pharma grade material replaces reagent-grade or technical-grade benzofuran derivatives in oral or injectable process trains

    Substitution of another grade or another alkylated benzofuran derivative should not proceed without a documented requalification package. The pharma grade product adds GMP traceability, particle size control, elemental impurity control, and endotoxin control. The table below summarizes the operational differences.

    AttributePMDBF Pharma Grade APITechnical GradeReagent Grade
    Assay98.0%–102.0%typically ≥90.0%typically ≥95.0%
    Residual solventsICH Q3C controllednot controlledlimited control
    Elemental impuritiesICH Q3D, USP <232>/<233>not routinely testednot routinely tested
    Bacterial endotoxins≤0.25 EU/mg injectablenot testednot tested
    Particle size D90controlled at ≤250 μm oral / ≤50 μm injectablevariablevariable
    GMP batch traceabilityICH Q7, change control, stability commitmentabsentabsent

    Differences from other benzofuran derivatives are structural as well as grade-based. The 2,2,4,6,7-methyl substitution pattern is expected to alter susceptibility to oxidation and metabolic clearance compared with the unsubstituted benzofuran ring, but no published comparative metabolism study for this exact compound was available at the time of writing. A salt, hydrate, or prodrug form of a similar benzofuran should not be considered interchangeable with this free base unless a full ICH Q8 control strategy update is performed, including impurity profile, solubility, polymorphism, stability, and excipient compatibility. Process intermediates and technical grades may have lower assay, variable particle size, uncontrolled residual solvents, or no endotoxin testing; their use in injectable manufacturing is unacceptable without complete qualification.

    Storage and ordering controls complete the operational difference. The pharma grade material is stored in tight, light-resistant containers at 20–25°C, with controlled excursions to 15–30°C. If oxidative sensitivity is observed, nitrogen overlay and amber glass with desiccant are used. The retest period is assigned from long-term stability data generated under ICH Q1A; in the absence of a public stability dataset for this specific molecule, the manufacturer should not extrapolate a retest period from other benzofurans.

    Top